Anti-PD-1 antibodies such as pembrolizumab and nivolumab, as well as anti-PD-L1 antibodies like atezolizumab and durvalumab, have been approved for the treatment of advanced melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and other cancers making them the foremost therapeutic agents in the oncology field (54). This evidence concerns the gene CD274 and non-small cell lung carcinoma.